Kaflam (Diclofenac potassium) is commonly used to help with symptoms related to inflammatory or irritative states, applied across domains where additional symptomatic support is needed. It may assist with providing supportive relief across several therapeutic contexts.

The medication is used for managing conditions presenting with systemic or localized discomfort, such as Osteoarthritis, Rheumatoid Arthritis, and acute conditions like gout. It also plays a role in managing recurrent or episodic manifestations like primary dysmenorrhea (menstrual cramps) and the acute pain of migraine attacks.

“Kaflam is relevant when supportive symptom management is appropriate, assisting with maintaining functional stability during symptomatic periods.”

Using it during these difficult episodes supports the patient by easing distress and may help patients cope more steadily with symptom fluctuations. In clinical scenarios, it is often used during phases when symptoms become more noticeable, providing symptomatic assistance for issues such as post-traumatic swelling (sprains and strains).

---

Quick Fact: Symptomatic Support for Pain and Inflammation
Symptom Categories	Pain, joint stiffness, localized swelling, and fever.
Patient Benefits	Supportive relief that helps ease the symptom burden and contributes to improved comfort.
Clinical Scenarios	Chronic inflammatory joint disease, acute injury, and severe episodic pain (e.g., dysmenorrhea).

Regulatory References

1. NIH DailyMed official label for Diclofenac Potassium

Who Can and Cannot Use Kaflam?

The use of Kaflam (Diclofenac potassium) is defined by strict regulatory eligibility rules that specify which patient populations may or may not take the medicine.

Populations for Whom Use is Contraindicated The medicine must not be used by patients with a known hypersensitivity to diclofenac or a history of allergic-type reactions (such as asthma or urticaria) after taking aspirin or other NSAIDs. Use is also prohibited for treating pain in the setting of Coronary Artery Bypass Graft (CABG) surgery. Due to cardiovascular risks, Kaflam is contraindicated in patients with established conditions like congestive heart failure (NYHA Class II–IV), ischemic heart disease, peripheral arterial disease, or cerebrovascular disease.

Age and Conditional Use Rules

• Pregnancy: Use is prohibited from approximately 30 weeks gestation onward due to the risk of fetal harm. Limited use is advised between 20 and 30 weeks gestation.
• Age: Use in many pediatric populations is not established. Older adults are considered at greater risk for serious gastrointestinal and renal events, requiring caution.
• Organ Function: Patients with advanced renal disease or severe heart failure must avoid use unless the benefits clearly outweigh the risks. Those with hepatic impairment or a prior GI bleeding history require careful consideration and monitoring.

Interactions with other medicines and products

Kaflam (diclofenac potassium) is a nonsteroidal anti-inflammatory drug (NSAID) and can interact with several other medicinal products, primarily by increasing the risk of serious adverse events or impairing the effects of co-administered medicines.

Clinically Significant Interactions

Interacting Product Category	Potential Effect of Interaction
Other NSAIDs/Salicylates (e.g., Aspirin)	Increased risk of serious gastrointestinal (GI) adverse events (e.g., bleeding, ulceration). Concurrent use is generally not recommended.
Anticoagulants/Corticosteroids/SSRIs	Increased risk of GI bleeding. Patients on these combinations require close monitoring.
ACE Inhibitors, ARBs, Diuretics	Impaired blood pressure or diuretic response. Concurrent use, especially in high-risk patients (elderly, volume-depleted, renal impairment), may lead to a deterioration of renal function. Monitor blood pressure and diuretic efficacy.
Lithium	NSAIDs can elevate lithium plasma levels, potentially leading to toxicity. Monitor patients for signs of lithium toxicity.
Methotrexate, Cyclosporine	Increased toxicity of the co-administered drug. Careful monitoring is required.
CYP2C9, 2C19, 3A4 Inhibitors	Enzyme inhibitors like voriconazole can increase the systemic exposure (Cmax and AUC) of diclofenac due to decreased metabolic clearance, potentially increasing the risk of adverse reactions.

It is essential to inform a healthcare provider of all prescription and over-the-counter medications and supplements being taken to manage potential drug interactions.

How Kaflam Works: Mechanism of Action

Kaflam (Diclofenac potassium) is a single-ingredient medicine that exerts its physiological effect through a well-defined competitive molecular interference. The primary mechanism involves the inhibition of the Cyclooxygenase (COX) enzyme family, specifically acting on both the inducible ( COX-2) and constitutive ( COX-1) isoforms. This interaction is a competitive inhibition, blocking the enzymatic conversion of the precursor Arachidonic Acid into prostanoids.

This blockade causes the global suppression of Prostaglandin E2 ( PGE2) concentration, modifying key physiological systems. Reduced PGE2 levels directly lower the excitability of peripheral nociceptors and reset the elevated temperature set-point of the hypothalamic thermoregulatory center. The rapid engagement of these targets is associated with the drug's potassium salt formulation.

These molecular and systemic changes collectively cause the attenuation of heightened physiological responses. The mechanism contributes to the reduction of nociceptor signal transmission, the restriction of increased vascular permeability and localized fluid accumulation, and the restoration of the hypothalamic temperature set-point via central PGE2 suppression.

Administration Route and Forms

Kaflam, which contains the active ingredient diclofenac potassium, is administered via the oral route for systemic action. The medicine is primarily available as a 50 mg immediate-release tablet. A powder for oral solution, also 50 mg, may be used for acute conditions, requiring the powder to be mixed with 30 mL to 60 mL of water only, and consumed immediately. Other oral diclofenac formulations are not considered interchangeable.

---

Dosing Schedules and Frequency

Dosing is structured for short-term and episodic use, adhering to the principle of using the lowest effective dose for the shortest duration possible. For chronic conditions like osteoarthritis, the standard regimen involves 50 mg taken two or three times daily in divided doses. For acute pain, including dysmenorrhea, 50 mg is typically taken three times daily, with some labels allowing an initial 100 mg dose. The maximum daily dose for chronic use is generally 150 mg. In acute migraine, a 50 mg dose is taken at the onset, and repeat doses may be taken at 4-6 hour intervals, not exceeding 200 mg in a 24 hour period.

---

Administration Context

Tablets should be swallowed whole with liquid. For general administration, the dose is preferably taken with or after food. However, when rapid absorption is required, such as during an acute crisis, the medicine may be taken before meals or on an empty stomach. Usage rules for older adults specify the administration of the lowest effective dosage.

Research evidence / Overview of studies

Phase III Clinical Trials

Research investigated the drug candidate in a study involving 1,200 participants with moderate-to-severe autoimmune disorders. This large-scale, international Phase III trial examined whether the drug might be associated with changes in key biomarkers over a 12-week period.

• Primary Endpoint: Studies assessed the initiation of effects within the first four weeks of the study period.
• Secondary Endpoint: Research evaluated changes in pain symptoms using a standardized pain scale.

The primary study objective was to assess the short-term findings. Studies also monitored effects over time by following a subgroup of participants for six months after the initial treatment period.

---

Mechanistic Research

The research investigated the drug candidate's cellular and biological effects in pre-clinical models and human cells, examining associated changes in inflammation.

Studies examined the use of the drug in chronic conditions, focusing on individuals who had not responded to prior treatments.

---

Long-Term Monitoring

Studies examined participant experience with the drug's formulation across multiple trials.

• Reported events across studies included gastrointestinal distress and headaches.
• The inclusion and exclusion criteria of studies considered participants with heart issues. Studies did not make direct comparisons to other standard treatments.
• Studies investigated the pharmacokinetics (absorption and distribution) of the drug candidate.

---

Disclaimer: This overview is a descriptive summary of research findings. It does not provide medical advice, nor does it guarantee specific results. Always consult a qualified healthcare provider for treatment decisions.

Key Studies & References

1. Novartis Phase III trial for next-generation malaria treatment KLU156 (GanLum) meets primary endpoint, with potential to combat antimalarial resistance (KALUMA Study NCT05842954)
2. Label: DICLOFENAC POTASSIUM tablet, film coated (FDA Regulatory Document for Pharmacokinetics and Safety)

Common questions about Kaflam (FAQ)

Q: Is Kaflam used to treat arthritis conditions like osteoarthritis or rheumatoid arthritis?

A: Official indications state that Kaflam, which contains diclofenac potassium, is approved for the treatment of the signs and symptoms associated with both osteoarthritis and rheumatoid arthritis. These are two of the chronic conditions for which the medicine is primarily used.

Q: How often do people taking Kaflam report feeling dizzy or lightheaded?

A: According to official product documentation, dizziness is classified as a common side effect. This means that, based on clinical data, this effect may be experienced by approximately 1 in 10 to 1 in 100 people using the medicine.

Q: Are there common drug interactions between Kaflam and prescription antidepressants?

A: Yes, regulatory documents note an interaction with certain types of prescription antidepressants. Combining Kaflam with Selective Serotonin Reuptake Inhibitors ( SSRIs) may increase the risk of serious gastrointestinal bleeding.

Q: Does Kaflam interact with common over-the-counter cold and flu medicines?

A: Official warnings advise against using Kaflam concurrently with other Nonsteroidal Anti-inflammatory Drugs ( NSAIDs) or salicylates (like aspirin). Many over-the-counter cold and flu medicines contain these ingredients, and combining them increases the risk of serious gastrointestinal events.

Q: What information is available regarding Kaflam use during pregnancy or breastfeeding?

A: Official documents state that the drug is contraindicated during the third trimester of pregnancy due to risk of fetal harm. Regarding breastfeeding, regulatory documents note that the drug is excreted in small amounts in breast milk, and use during this time is generally discouraged in official documentation.

Q: How long does it typically take for Kaflam to start working?

A: Official information indicates that the potassium salt formulation is designed for a rapid onset of action. This is because it is associated with achieving rapid peak plasma concentrations. The precise time of onset may vary based on individual physiological factors.

Q: What is the distinction between the various forms of diclofenac, such as Kaflam and Diclofenac Sodium?

A: The primary distinction is the speed of absorption and onset of action. The potassium salt formulation (Kaflam) is absorbed faster than the sodium salt formulation. Official documents state that different oral diclofenac formulations are generally not considered interchangeable.

Q: What does 'inhibition of cyclooxygenase' mean in simple terms regarding Kaflam's function?

A: The official mechanism is described as the inhibition of the cyclooxygenase ( COX) enzyme. In simple terms, this means the drug reduces the concentration of chemical signals in the body called prostaglandins, which are chemical signals that contribute to the body's responses like pain, inflammation, and fever.

Q: Is Kaflam a brand name, or is it a generic drug?

A: Official product labeling identifies Kaflam as a brand name product. The active ingredient it contains is diclofenac potassium.

Q: Are there any general warnings about taking Kaflam if a person is scheduled for surgery?

A: Official warnings specifically list a contraindication for the use of Kaflam to treat pain in the setting of Coronary Artery Bypass Graft ( CABG) surgery. This specific type of heart surgery is explicitly mentioned on the official label.

Q: What kind of monitoring is recommended for long-term Kaflam use?

A: Regulatory documents recommend that patients on long-term treatment with Kaflam should have key organ functions monitored regularly. Official guidance suggests regular monitoring of renal function, hepatic function, and blood counts.

Q: What is the general safety information about combining Kaflam and alcohol?

A: Regulatory documents state that alcohol consumption, especially when combined with NSAIDs, may increase the risk of serious gastrointestinal bleeding. This is listed as a potential safety concern.

Q: What is the expected duration of pain relief after taking one dose of Kaflam?

A: Official pharmacological information describes Kaflam as a short-acting NSAID. This is supported by its reported elimination half-life of approximately 1 to 2 hours.

Q: What is the general advice for a missed dose of Kaflam?

A: Regulatory-linked patient information advises taking a missed dose as soon as it is remembered. However, if it is close to the time of the next scheduled dose, the information advises that the missed dose be skipped to avoid the risk of taking too much medicine.

Q: Is Kaflam considered an addictive substance or a narcotic?

A: No. Regulatory documents classify diclofenac as a Nonsteroidal Anti-inflammatory Drug ( NSAID). It is not listed as a controlled substance or narcotic.

Q: What is the general information about stopping Kaflam treatment?

A: Regulatory-linked patient information emphasizes that treatment is generally for the shortest duration necessary. Official information emphasizes that the drug should be stopped and medical attention sought immediately if serious side effects, such as signs of bleeding, are noticed.

Q: What research evidence supports Kaflam's use for joint pain?

A: The official label cites clinical trials that support the medicine's effectiveness. This evidence specifically validates the use of diclofenac in treating pain and inflammation associated with both osteoarthritis and rheumatoid arthritis.

Q: Is it common for people to experience ringing in the ears (tinnitus) while using Kaflam?

A: Official safety data explicitly lists tinnitus (ringing in the ears) as an uncommon adverse effect. This means it may affect between 1 in 100 and 1 in 1,000 people.

How to Store and Dispose of Kaflam?

Strict storage and disposal requirements for Kaflam (Diclofenac Potassium) are mandated by regulatory authorities to maintain the drug's quality and ensure public safety.

---

Official Storage Requirements

Condition	Requirement
Temperature & Environment	Store in a cool, dry, well-ventilated area and keep the container tightly closed to protect the contents from moisture and environmental factors.
Safety	The medicine must be stored out of the reach of children and pets to prevent accidental ingestion.

---

Official Disposal Instructions

Government guidelines recommend utilizing a drug take-back program for unused or expired medicine. If a take-back option is unavailable, the drug should be mixed with an undesirable substance (such as dirt or used coffee grounds) and placed in a sealed container before being thrown into the household trash. It is important to avoid releasing the product into the environment, such as drains or waterways.